Quick Answer
Climb Bio, Inc. reported Diluted EPS of $0.88 per share (loss) for fiscal year 2025.
Climb Bio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.88 | +42.5% |
| 2024 | -$1.53 | -17.7% |
| 2023 | -$1.30 | +24.4% |
| 2022 | -$1.72 | +59.4% |
| 2021 | -$4.24 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.19 | -46.2% | -46.2% |
| June 30, 2025 | -$0.13 | +92.8% | +58.1% |
| March 31, 2025 | -$0.31 | -416.7% | -138.5% |
| September 30, 2024 | -$0.13 | +13.3% | +92.8% |
| June 30, 2024 | -$1.81 | -852.6% | -2916.7% |
| March 31, 2024 | -$0.06 | +92.9% | +60.0% |
| September 30, 2023 | -$0.15 | +59.5% | +21.1% |
| June 30, 2023 | -$0.19 | +48.6% | +77.4% |
- Climb Bio, Inc. showed an increase of +42.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Climb Bio, Inc.’s diluted eps has grown by 79.2% (from $4.24 per share (loss) to $0.88 per share (loss)).
- The most recent figure is from Climb Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: